APA (7th ed.) Citation

Song, J. H., Kim, C., Chung, Y., & Kim, H. R. (2025). Efficacy and Safety of Switching from Adalimumab Originator to SB5 Biosimilar in Noninfectious Uveitis: Early Clinical Outcomes. Journal of Clinical Medicine, 14(22), 8179. https://doi.org/10.3390/jcm14228179

Chicago Style (17th ed.) Citation

Song, Ji Hun, Chungwoon Kim, Yoo-Ri Chung, and Hae Rang Kim. "Efficacy and Safety of Switching from Adalimumab Originator to SB5 Biosimilar in Noninfectious Uveitis: Early Clinical Outcomes." Journal of Clinical Medicine 14, no. 22 (2025): 8179. https://doi.org/10.3390/jcm14228179.

MLA (9th ed.) Citation

Song, Ji Hun, et al. "Efficacy and Safety of Switching from Adalimumab Originator to SB5 Biosimilar in Noninfectious Uveitis: Early Clinical Outcomes." Journal of Clinical Medicine, vol. 14, no. 22, 2025, p. 8179, https://doi.org/10.3390/jcm14228179.